摘要
目的观察甲磺酸阿帕替尼治疗二线治疗失败的晚期非小细胞肺癌的临床疗效及不良反应。方法 30例患者接受甲磺酸阿帕替尼治疗,初始剂量为500mg/d,若无严重不良反应,服药2周后增量至750mg/d,并维持治疗,4周后通过影像学检查、检测癌胚抗原(CEA)、糖类抗原199(CA199)、CA125、鳞状细胞癌抗原(SCC)结果评价其近期疗效。结果 30例接受甲磺酸阿帕替尼治疗的患者中,完全缓解0例,部分缓解9例,稳定16例,进展3例,因严重不良反应停药2例,客观有效率32.1%(9/28),疾病控制率89.3%(25/28)。治疗4周后血清CEA、CA199、CA125、SCC较前均明显下降(P<0.05)。不同转移瘤预后的有效率差异无统计学意义(P>0.05)。不良反应主要是高血压、口腔黏膜炎、纳差乏力,发生率分别为33.3%、30.0%和23.3%。结论甲磺酸阿帕替尼治疗二线治疗失败的晚期非小细胞肺癌近期疗效可,不良反应可控制,可应用于晚期非小细胞肺癌并可研究其长期疗效。
Objective To observe the clinical efficacy and adverse reactions of apatinib for second-line treatment failure of advanced non-small cell lung cancer.Methods Thirty patients received treatment of apatinib at a dose of 500mg/day for two weeks,then increased to 750mg/day if they could tolerate and maintain the therapy.The efficacy was evaluated by the imaging and testing tumor such as markers including CEA,CA199,CA125 and SCC.Results The clinical evaluation of the patients were complete remission 0case,partial remission 9 cases,steady 16 cases,progess 3cases,2cases terminated the treatment due to adverse reactions,and the objective response rate was 32.1%（9/28）,disease control rate was 89.3%（25/28）.After four weeks′treatment,CEA,CA199,CA125 and SCC were significantly reduced than the previous（P〈0.05）.The effective rate on the prognosis of different metastatic sites were no significant difference（P 0.05）.The main toxicities were hypertension,oral mucositis and poor appetite（33.3%,30.0% and 23.3%）.Conclusion The treatment of apatinib in second-line treatment failure of advanced non-small cell lung cancer has better clinical efficacy,and toxicity could be controlled,so it was worth evaluating the long-term efficacy of apatinib for advanced non-small cell lung cancer.
出处
《临床荟萃》
CAS
2017年第10期877-880,共4页
Clinical Focus
关键词
甲磺酸阿帕替尼
癌
非小细胞肺
疗效
副作用
apatinib
carcinoma
non-small cell lung
efficacy
adverse effects
